Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand Q1 2026 royalty revenue up 56% to $43.0 million; GAAP net loss $13.3 million

Positive Impact 3 of 5 earnings Written later

Ligand reported first-quarter 2026 total revenue of $51.7 million, up 14% from $45.3 million a year earlier, driven by royalties of $43.0 million. The GAAP net loss narrowed to $13.3 million, or $0.67 per share, from $42.5 million, or $2.21 per share, but the company also recorded a $49.2 million non-cash loss on its Pelthos investments. Ligand reaffirmed its 2026 guidance, which was raised on April 27, 2026 to reflect the pending XOMA Royalty acquisition expected to close in the third quarter of 2026.

Key points

  • Total revenue $51.7 million vs. $45.3 million; royalties $43.0 million vs. $27.5 million (up 56%)
  • Captisol sales fell to $8.7 million from $13.5 million, due to the timing of customer orders
  • Adjusted net income $34.6 million, or $1.63 per diluted share, vs. $26.6 million, or $1.33, a year earlier
  • 2026 guidance reaffirmed: adjusted EPS $8.50 to $9.50, royalty revenue $225 million to $250 million, total revenue $270 million to $310 million

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:03 AM ET
Accession number0000886163-26-000030

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.